Literature DB >> 20644213

Presence of free radicals in intracameral agents commonly used during cataract surgery.

David Lockington1, Elisabeth C A Macdonald, David Young, Philip Stewart, Muriel Caslake, Kanna Ramaesh.   

Abstract

BACKGROUND: Free radicals are known to cause cellular damage and are present in ophthalmic preparations. Corneal defence mechanisms are bypassed in intra-ocular surgery. We evaluated commonly used intracameral agents to ascertain the presence of free radicals and investigate the possibility of anterior segment and endothelial toxicity.
METHODS: Samples of 19 commonly used intracameral preparations were analysed for total free radical presence on an Instrument Laboratory IL600 using a Randox Kit for Total Antioxidant Status (RANDOX Laboratories Ltd, Crumlin, UK).
RESULTS: Free radical concentrations for the 19 intracameral agents ranged from 0 to 3.59 mmol/l, with median value of 0.34 mmol/l (mean value 0.933±1.19 mmol/l). Phenylephrine had the highest presence of free radicals, which were considerably higher than those for 0.5% hydrogen peroxide at all tested dilutions. Other notable results included cefuroxime (0.61 mmol/l), 2% undiluted lidocaine (0.34 mmol/l) and bevacizumab (0.59 mmol/l).
CONCLUSION: The results indicate that free radicals are present in intracameral surgical agents and some are in the order of 0.5% hydrogen peroxide. The risks of endothelial damage must be considered when using multiple intracameral preparations in complicated cataract surgery. Free radicals in intracameral preparations may be a contributing cause in cases of toxic anterior segment syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644213     DOI: 10.1136/bjo.2009.171009

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Comment on hydration with Cefuroxime-a method for sealing a small leaking corneal perforation.

Authors:  Murat Aslankurt; Osman Çekiç
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

2.  Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?

Authors:  D Lockington; E C A Macdonald; P Stewart; D Young; M Caslake; K Ramaesh
Journal:  Eye (Lond)       Date:  2012-03-02       Impact factor: 3.775

3.  Quantifying the real-world cost saving from using surgical adjuncts to prevent complications during cataract surgery.

Authors:  Aaron Jamison; Larry Benjamin; David Lockington
Journal:  Eye (Lond)       Date:  2018-06-06       Impact factor: 3.775

4.  Acute macular edema and serous detachment on the first day after phacoemulsification surgery: A case report.

Authors:  Edyta Chlasta-Twardzik; Anna Nowińska; Edward Wylęgała
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-01

5.  Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery.

Authors:  Stuart Guthrie; Thomas Jensen; Richard C Hartley; Kanna Ramaesh; David Lockington
Journal:  Eye (Lond)       Date:  2018-06-15       Impact factor: 3.775

6.  Evaluating the safety of intracameral bevacizumab application using oxidative stress and apoptotic parameters in corneal tissue.

Authors:  Ali Akal; Turgay Ulas; Tugba Goncu; Muhammet Emin Guldur; Sezen Kocarslan; Abdullah Taskin; Hatice Sezen; Kudret Ozkan; Omer Faruk Yilmaz; Hakan Buyukhatipoglu
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

7.  Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime.

Authors:  Burçin Çakır; Erkan Celik; Nilgün Özkan Aksoy; Özlem Bursalı; Turgay Uçak; Erdinç Bozkurt; Gursoy Alagoz
Journal:  Clin Ophthalmol       Date:  2015-03-17

8.  The short to medium-term risks of intracameral phenylephrine.

Authors:  Gwyn S Williams; Mahmoud Radwan; Shwan Kadare; Christopher P R Williams
Journal:  Middle East Afr J Ophthalmol       Date:  2012-10

Review 9.  Toxic anterior segment syndrome-an updated review.

Authors:  Choul Yong Park; Jimmy K Lee; Roy S Chuck
Journal:  BMC Ophthalmol       Date:  2018-10-25       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.